Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

NCT00301795 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

52

Enrollment

NIH

Sponsor class

Conditions

Stage III Grade 1 Follicular Lymphoma
Stage III Grade 2 Follicular Lymphoma
Stage III Grade 3 Follicular Lymphoma
Stage IV Grade 1 Follicular Lymphoma
Stage IV Grade 2 Follicular Lymphoma
Stage IV Grade 3 Follicular Lymphoma

Interventions

BIOLOGICAL: oblimersen sodium
BIOLOGICAL: rituximab
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)